Understanding how dengue vaccines and infections create lasting immunity
Official title: Durability and mechanisms of dengue vaccine and infection mediated immunity
Funded at St. Louis VA Medical Center · NIH-11043316 · Data updated 2026-11-12
This study is looking at how well the TDV/TAK003 dengue vaccine helps your immune system fight off dengue compared to getting the virus naturally, especially for people who haven't been infected before, and it will track your immune response and health over the years to see how long that protection lasts.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Louis VA Medical Center NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01CX002688-02 |
| Project ID | NIH-11043316 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have never been infected with dengue virus and are at risk of exposure, such as veterans or residents in endemic areas.
✕Less likely to help
Patients who have previously been infected with dengue virus may not benefit from this research as the focus is on those who are seronegative.
What this research studies
This research investigates the immune responses generated by the TDV/TAK003 dengue vaccine and how they compare to immunity developed after natural dengue infections. It focuses on the durability of the immune response, particularly the production of specific antibodies and T cells that can protect against future infections. The study aims to understand the mechanisms behind antibody-dependent enhancement (ADE) of disease and how the vaccine can provide safe and effective protection, especially for those who have never been infected before. Patients may be monitored over several years to assess their immune responses and overall health.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer dengue vaccine that provides long-lasting immunity for individuals, particularly those at risk of severe dengue disease.
How similar studies have gone: Previous research has shown promising results with the TDV/TAK003 vaccine, indicating it may provide a novel and effective approach to dengue prevention.
Where this research is happening
-
St. Louis VA Medical Center
St. Louis, United States Active
Researchers
- Principal investigator: George, Sarah — St. Louis VA Medical Center
- Study coordinator: George, Sarah
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.